What does SARC-F stand for?

SARC-F is an acronym for its five questionnaire items: S = Strength (lifting/carrying), A = Assistance in walking (ambulation), R = Rise from a chair, C = Climb stairs, F = Falls. Each letter maps directly to a functional domain affected by muscle loss (sarcopenia). The name also references 'SARC' (sarcopenia) and 'F' (the functional screening approach).

What is the difference between SARC-F and SARC-CalF?

SARC-CalF adds a calf circumference measurement to the 5 standard SARC-F questions. Cut-offs: <34 cm in men, <33 cm in women. If calf circumference is below the threshold, 10 points are added to the SARC-F score (maximum total 20 points), and the positive screen threshold increases to ≥11 for SARC-CalF combined. SARC-CalF improves sensitivity compared to SARC-F alone (approximately 60–75% sensitivity vs. 20–60% for SARC-F), making it better at detecting early sarcopenia at the cost of slightly more complexity. AWGS 2019 recommends SARC-CalF as an alternative first-step screen to SARC-F, particularly when improved sensitivity is desired.

Who should be screened with SARC-F?

Recommended screening populations: (1) All adults aged ≥65 at annual wellness visits or clinic encounters; (2) Patients with unexplained weight loss, functional decline, or increased fall frequency; (3) Pre-operative assessment for major elective surgery (≥65 years); (4) Patients with chronic conditions associated with sarcopenia: COPD, heart failure, liver cirrhosis, CKD, diabetes, cancer, rheumatoid arthritis; (5) Post-hospitalization follow-up (acute illness accelerates sarcopenia); (6) Patients starting long-term corticosteroid therapy; (7) Any patient in whom impaired grip strength or slow gait speed is noted. EWGSOP2 recommends universal SARC-F screening in all older adults presenting to healthcare settings.

What is the relationship between sarcopenia and falls?

Sarcopenia and falls are tightly linked: reduced lower extremity muscle strength impairs balance reactions and postural recovery; slow gait speed (a marker of sarcopenia) is the strongest single predictor of falls and adverse outcomes in older adults; muscle weakness of the quadriceps directly impairs knee stability during walking and stair climbing. Sarcopenia is an independent risk factor for falls, fractures, and hospitalization. Conversely, falls can accelerate sarcopenia through reduced physical activity during recovery and fear-of-falling-mediated deconditioning. Treating sarcopenia (resistance training, protein) reduces fall incidence — several RCTs of progressive resistance training in older adults show 30–40% reduction in fall rates.

What is the EWGSOP2 sarcopenia diagnostic algorithm?

EWGSOP2 (2019) recommends a Find-Assess-Confirm-Severity (FACS) approach: (1) FIND: Use SARC-F to identify probable cases (screen positive = ≥4). (2) ASSESS: Measure grip strength (cut-off <27 kg men, <16 kg women) or 5-times sit-to-stand (<12 seconds). Low strength = 'probable sarcopenia' — start intervention now. (3) CONFIRM: Measure muscle quantity/quality via DXA (ALMI <7.0/5.5 kg/m²) or BIA. Low strength + low quantity = confirmed sarcopenia. (4) SEVERITY: Assess physical performance (gait speed ≤0.8 m/s, SPPB ≤8, TUG ≥20 s). Low strength + low quantity + low performance = severe sarcopenia. Treatment indicated from the 'probable' stage onwards — do not wait for full confirmatory testing to initiate exercise and nutrition interventions.

Can sarcopenia be reversed?

Yes — sarcopenia is partially reversible, particularly with early intervention. Progressive resistance training consistently improves muscle strength and physical function in older adults with sarcopenia, even at ages 80–90+. Muscle mass is harder to increase than muscle strength (neural adaptation drives early strength gains before hypertrophy becomes prominent), but measurable muscle mass increases are achievable with 12+ weeks of progressive resistance training combined with adequate protein intake. The degree of reversibility depends on severity and duration of sarcopenia, comorbidities, nutritional status, and ability to adhere to exercise programming. Early-stage sarcopenia (positive SARC-F, low grip) is substantially more reversible than end-stage severe sarcopenia with extensive muscle wasting.

What role do medications play in sarcopenia?

Several medication classes contribute to or accelerate sarcopenia: Corticosteroids (prednisone/dexamethasone) — suppress muscle protein synthesis and directly cause muscle wasting; myopathy is dose- and duration-dependent. Statins — associated with statin-induced myopathy (myalgia, CK elevation, and in severe cases rhabdomyolysis) in susceptible patients. Diuretics and ACE inhibitors — can cause electrolyte derangements (potassium, magnesium) that impair muscle function. Opioids — induce sedation and reduce physical activity, accelerating deconditioning. Androgen deprivation therapy (ADT) in prostate cancer — causes significant muscle wasting and fat gain. Review medications contributing to muscle loss in patients with positive SARC-F and consider risk-benefit reassessment with the prescribing team.

Online Medical Tools — SARC-F

Printed on 9/3/2026

For informational purposes only. This is not medical advice.

Geriatrics

SARC-F

SARC-F is a quick questionnaire-based screening tool for sarcopenia risk in older adults and medically complex populations. A score of 4 or higher commonly indicates likely sarcopenia risk and supports further evaluation of muscle strength and performance.

Formula: SARC-F = sum of 5 items scored 0-2 each; total range 0-10.

Strength (difficulty lifting/carrying 10 lb or ~4.5 kg)

Assistance in walking across a room

Rise from a chair or bed

Climb a flight of 10 stairs

Falls in the past year

Save your results with a free account

Keep a history of calculations, favorite tools, and access your dashboard anytime.

Create free account Sign in

How It Works

Ask the patient the five SARC-F questions

SARC-F is an interviewer-administered or self-completed 5-item questionnaire. The five items with their response options are: (1) Strength — 'How much difficulty do you have in lifting and carrying 10 pounds (4.5 kg)?' Response: None (0), Some difficulty (1), A lot of difficulty or unable (2). (2) Assistance in walking — 'How much difficulty do you have walking across a room?' Response: None (0), Some difficulty (1), A lot of difficulty, use aids, or unable without help (2). (3) Rise from a chair — 'How much difficulty do you have transferring from a chair or bed?' Response: None (0), Some difficulty (1), A lot of difficulty or unable without help (2). (4) Climb stairs — 'How much difficulty do you have climbing a flight of 10 stairs?' Response: None (0), Some difficulty (1), A lot of difficulty or unable (2). (5) Falls — 'How many times have you fallen in the past year?' Response: None (0), 1–3 falls (1), 4 or more falls (2). The SARC-F can be self-completed in approximately 1–2 minutes, making it suitable for waiting room pre-screening, outpatient clinic administration, or completion by community health workers.

Sum the five item scores (total 0–10)

Add the responses from all five SARC-F items. Each item is scored 0, 1, or 2, for a total score range of 0–10. A score of 0 indicates no self-reported functional limitation across strength, walking, chair transfer, stair climbing, or falls — very low probability of clinically significant sarcopenia. A score of 1–3 indicates some self-reported limitations but falls below the positive screen threshold — note individual items with scores of 1–2 as these may warrant monitoring. A score of 4 or above is the standard threshold for a positive SARC-F screen, indicating probable sarcopenia risk and warranting confirmatory objective assessment. Higher scores within the positive range (e.g., 7–10) indicate more severe functional limitation and higher likelihood of confirmed sarcopenia with muscle strength and performance deficits.

Interpret the screen result and plan confirmatory assessment

SARC-F score interpretation: 0–3 = Screen negative. Low probability of sarcopenia. In community-dwelling older adults over 65, repeat SARC-F screening annually or at clinical visits with any functional change. 4–10 = Screen positive. Probable sarcopenia risk. Proceed to confirmatory objective assessments per EWGSOP2 (European Working Group on Sarcopenia in Older People) diagnostic algorithm: (1) Muscle strength measurement — handgrip dynamometry (low strength: <27 kg men, <16 kg women) or 5-times sit-to-stand test (<12 seconds) as alternative. Low strength confirms 'probable sarcopenia' warranting intervention. (2) If strength is low: muscle quantity/quality assessment — DXA (appendicular lean mass index <7.0 kg/m² men, <5.5 kg/m² women) or BIA for body composition. (3) Physical performance — gait speed (≤0.8 m/s), [SPPB ≤8](/tools/sppb-score), or TUG ≥20 seconds. Low strength + low quantity = sarcopenia; add low performance = severe sarcopenia. Document SARC-F score, positive screen, and referral for objective evaluation in the clinical record.

Who Uses the SARC-F

Primary Care Sarcopenia Screening in Older Adults

Primary care physicians, geriatricians, nurse practitioners, physician assistants

Sarcopenia affects an estimated 10–16% of community-dwelling adults over 65 and up to 50% of those over 80. SARC-F is endorsed by EWGSOP2 (2019), AWGS (Asian Working Group for Sarcopenia 2019), and multiple geriatric medicine societies as the preferred initial screening tool for sarcopenia in primary care settings due to its speed (1–2 minutes), no equipment requirement, and validated positive screen cutoff (≥4). Annual SARC-F screening for all patients ≥65 during wellness visits identifies those needing confirmatory assessment. Positive screen triggers objective evaluation: handgrip strength, BIA or DXA, and gait speed. Earlier sarcopenia identification enables initiation of evidence-based interventions (resistance training, protein optimization) before severe disability develops.

Pre-Operative Functional Risk Assessment

Surgeons, anesthesiologists, geriatric surgery programs, perioperative nurses

Pre-operative sarcopenia (diagnosed or screened by SARC-F) is an independent predictor of post-operative complications, prolonged hospital length of stay, non-home discharge, and mortality in patients undergoing major elective surgery (colorectal, oncological, cardiovascular, orthopedic). SARC-F ≥4 before surgery identifies patients who benefit from pre-operative prehabilitation: structured resistance exercise and protein supplementation in the 4–8 weeks before surgery to improve muscle function and reduce surgical risk. Multiple enhanced recovery after surgery (ERAS) protocols for patients aged ≥65 include pre-operative sarcopenia screening as part of comprehensive geriatric assessment. SARC-F is practical in busy pre-assessment clinics due to its brief administration.

Chronic Disease and Oncology Sarcopenia Monitoring

Oncologists, hepatologists, cardiologists, pulmonologists, rheumatologists

Sarcopenia is prevalent in and prognostically important across multiple chronic disease conditions: liver cirrhosis (sarcopenia predicts decompensation and transplant outcomes), COPD (muscle wasting predicts exacerbation frequency and mortality), heart failure (cardiac cachexia), cancer (cachexia predicts chemotherapy toxicity and survival), and rheumatoid arthritis (inflammatory sarcopenia). SARC-F provides a quick, disease-agnostic screening tool that can be integrated into routine clinic follow-up visits for these patient populations. Positive SARC-F in these settings triggers specialist nutrition consultation, disease-specific rehabilitation referral, and consideration of sarcopenia in treatment planning (e.g., dose adjustment for chemotherapy agents with muscle wasting side effects).

Geriatric Oncology Assessment

Geriatric oncologists, oncology nurses, cancer care coordinators

Sarcopenia assessed by SARC-F or objective measures is one of the strongest predictors of chemotherapy toxicity, functional decline, and survival in older adults with cancer. The International Society of Geriatric Oncology (SIOG) recommends comprehensive geriatric assessment (CGA) — which includes sarcopenia screening — for all older adults before initiating cancer treatment. SARC-F ≥4 in cancer patients identifies those needing: oncologic rehabilitation referral, protein and caloric supplementation to prevent further muscle loss during treatment, individualized chemotherapy dosing, dose-reduction planning for neurotoxic agents, and advanced care planning discussion. Serial SARC-F monitoring during cancer treatment tracks functional trajectory.

Falls Prevention Clinics and Physiotherapy Assessment

Physiotherapists, falls prevention nurses, occupational therapists

Sarcopenia and falls risk are tightly linked — reduced muscle strength and mass directly impair postural stability and recovery from perturbations. SARC-F item 5 (falls) scores recent fall history, and a positive SARC-F screen often co-occurs with elevated [TUG](/tools/get-up-and-go), [SPPB](/tools/sppb-score), and [Morse Fall Scale](/tools/morse-fall-scale) scores. In falls prevention clinics and physiotherapy assessment, SARC-F provides a structured screening question set that covers multiple fall-relevant functional domains (strength, walking, chair transfer, stair climbing, fall history) in one tool. SARC-F results guide physical therapy goal-setting: patients scoring high on specific items (e.g., Strength=2, Rise from Chair=2) have resistance training targets directly mapped to their functional deficits.

Pro Tips

SARC-F is a screener, not a diagnostic tool — always confirm positives objectively

A SARC-F score ≥4 indicates probable sarcopenia risk and triggers objective confirmatory assessment — it does not diagnose sarcopenia. The EWGSOP2 diagnostic algorithm requires low muscle strength (handgrip or chair stand) and/or low muscle quantity (DXA or BIA) to confirm the diagnosis. Do not label a patient as 'sarcopenic' and initiate formal interventions based on SARC-F alone. The screen is a gateway to efficient identification of who needs confirmatory testing, not a standalone diagnostic criterion.

SARC-F has high specificity but moderate sensitivity — negative result doesn't rule out early sarcopenia

SARC-F has specificity of approximately 70–90% (few false positives) but sensitivity of only approximately 20–60% (many false negatives, particularly in early sarcopenia). This means SARC-F is good at confirming probable sarcopenia risk when positive, but a negative score does not rule out sarcopenia in patients with objective evidence of muscle weakness or wasting. For patients with clinical concern (unexplained weight loss, observed weakness, functional decline) despite SARC-F score below 4, proceed directly to objective strength testing (handgrip) — do not rely on the negative SARC-F screen alone.

The falls item alone (item 5) has independent falls prediction value

SARC-F item 5 (falls in the past year: 0 = none, 1 = 1–3 falls, 2 = 4+ falls) correlates strongly with ongoing fall risk independent of the total SARC-F score. Any patient who scores 2 on item 5 (4 or more falls in the past year) warrants a comprehensive multifactorial falls assessment regardless of their total SARC-F score. The USPSTF and AGS/BGS guidelines both recommend intervention for older adults with 2+ falls in the past year or any fall with injury. Use the falls item as a fall risk flag alongside its contribution to the sarcopenia screen.

Pair SARC-F with objective grip strength for best diagnostic efficiency

The EWGSOP2-recommended rapid sarcopenia identification pathway is SARC-F screening (≥4) followed by grip strength measurement. The combination of SARC-F ≥4 plus low handgrip strength (<27 kg men, <16 kg women) has significantly higher positive predictive value for confirmed sarcopenia than either measure alone. A portable hand dynamometer is inexpensive (<$100), quick to use (30-second test), and can be deployed in primary care or clinic settings. If a dynamometer is not available, the 5-times sit-to-stand test (<12 seconds for 5 repetitions = adequate strength) is a validated alternative performance-based measure.

Resistance exercise is the single most evidence-based sarcopenia intervention

Positive SARC-F screen should trigger referral for structured resistance training — this is the intervention with the most robust evidence for reversing muscle weakness and improving physical function in sarcopenia. Recommended: 2–3 sessions per week of progressive resistance training targeting all major muscle groups (leg press, seated row, chest press, hip extension); target load ≥70% of 1-repetition maximum for optimal muscle protein synthesis stimulus. Even in frail older adults, appropriately supervised progressive resistance training is safe and effective. Protein optimization (≥1.2 g/kg/day, with leucine-rich protein sources) is the essential nutritional adjunct — protein without exercise is less effective than the combination.

Protein intake is the key nutritional intervention for sarcopenia

Inadequate dietary protein is a major driver of sarcopenia progression. Current PROT-AGE guidelines recommend protein intake ≥1.0–1.2 g/kg/day for older adults to maintain muscle mass, increasing to 1.2–1.5 g/kg/day for those with sarcopenia risk and ≥1.5 g/kg/day in those with active chronic disease or injury. Leucine-enriched whey protein supplements taken within 30 minutes after resistance exercise maximize muscle protein synthesis signaling. Essential amino acid supplementation may be helpful for patients with very low dietary protein intake. A positive SARC-F screen should trigger dietary assessment and dietitian referral for protein optimization.

SARC-F is validated and comparable across ethnic groups — key for diverse populations

SARC-F has been validated in multiple ethnic groups including European, East Asian (Chinese, Japanese, Korean), South Asian, and Latin American populations. The positive screen threshold of ≥4 performs comparably across these groups, making SARC-F one of the few geriatric screening tools that does not require population-specific cutoff recalibration. However, the criterion thresholds for objective confirmation (handgrip, appendicular lean mass) DO differ by sex and ethnicity — use EWGSOP2 thresholds for European populations and AWGS2 thresholds for Asian populations.

Vitamin D deficiency is a modifiable sarcopenia risk factor worth checking

Vitamin D receptors are expressed in skeletal muscle, and vitamin D deficiency (25-hydroxyvitamin D <50 nmol/L) is associated with muscle weakness, impaired muscle fiber composition, and increased fall risk. Correction of vitamin D deficiency (target 25-OHD >75 nmol/L) has modest benefit for muscle function and fall prevention in deficient older adults. Check vitamin D status (25-hydroxyvitamin D) in all patients with positive SARC-F screen and supplement if deficient: 1,000–2,000 IU/day vitamin D3 to reach and maintain adequacy. Vitamin D supplementation alone (without exercise) has limited effect on muscle mass — it should be part of a multimodal intervention.

Common Questions About Your Results

Yes. SARC-F has moderate sensitivity, meaning it misses a meaningful proportion of patients with objective sarcopenia (false negatives). A score of 3 is below the positive screen threshold but does not exclude sarcopenia. If clinical judgment suggests muscle weakness or wasting — reduced grip strength noted on examination, difficulty with transfers observed, significant unintentional weight loss, severe frailty — proceed to objective assessment regardless of SARC-F score. The EWGSOP2 pathway is: if clinical concern exists, measure grip strength directly (cut-off <27 kg men, <16 kg women). Consider SARC-F a screening aid, not a clinical override.

Sarcopenia and frailty are distinct but overlapping conditions. Sarcopenia is specifically defined by low muscle mass combined with low muscle strength and/or low physical performance — it is a disease of muscle. Frailty is a broader vulnerability state characterized by reduced reserve across multiple physiological systems (physical, cognitive, immune, metabolic), typically assessed by the Fried Phenotype (fatigue, resistance, ambulation, illnesses, weight loss) or Frailty Index. Sarcopenia is a major contributor to physical frailty but not identical to it: a patient can have sarcopenia without meeting Fried frailty criteria, and frailty can exist without meeting sarcopenia diagnostic thresholds. Both are independently predictive of adverse outcomes and both are potentially modifiable with exercise and nutrition.

Yes — SARC-F can be administered to hospitalized patients, though interpretation requires care. Acute illness causes reversible functional decline that may temporarily elevate SARC-F scores above the true baseline. A SARC-F ≥4 during acute hospitalization may reflect the current illness state rather than chronic sarcopenia. Best practice: complete SARC-F early in admission to capture the pre-illness baseline (or ask about function 2 weeks before the acute event), and repeat SARC-F after clinical recovery (at outpatient follow-up or rehabilitation) for a stable post-illness assessment. Serial SARC-F tracking before and after hospitalization quantifies illness-related functional decline.

SARC-CalF adds a calf circumference measurement to the standard SARC-F questionnaire. Calf circumference is a simple, inexpensive proxy measure of lower leg muscle mass (cut-offs: <34 cm in men, <33 cm in women for low muscle mass). The combined SARC-CalF score (SARC-F score + 10 additional points if calf circumference is below threshold) improves sensitivity for sarcopenia detection compared to SARC-F alone, while maintaining similar specificity — addressing one of the main limitations of SARC-F (low sensitivity in early sarcopenia). SARC-CalF requires only a measuring tape and takes less than 5 minutes. AWGS 2019 endorses SARC-CalF as an alternative first-step screen. SARC-CalF is available as a separate calculator on this site: [SARC-CalF](/tools/sarc-calf).

SARC-F is an excellent serial monitoring tool for functional trajectory in older adults because it is brief, sensitive to change over months, and does not require equipment. Document SARC-F score and individual item scores at each assessment. Track: total score trend (stable vs. worsening); which items change (Strength, walking, transfers, stairs, falls); and whether the patient has crossed the positive screen threshold (below 4 → 4+ is a meaningful crossing requiring intervention). In rehabilitation settings, SARC-F improvement (score decreasing from 6 to 3) documents functional gains from exercise programming. In oncology, SARC-F worsening during treatment can signal sarcopenic progression requiring nutritional and rehabilitation escalation.

Evidence-Based Methodology

SARC-F developed and validated by Malmström TK and Morley JE (J Am Med Dir Assoc 2013) in a primary care older adult population. Validation meta-analysis: Ida S et al. (J Am Med Dir Assoc 2018) — pooled sensitivity 21%, specificity 90%, AUC 0.74 vs. EWGSOP1 criteria. AWGS 2019 endorsement: Chen LK et al. (J Am Med Dir Assoc 2020). EWGSOP2 recommendation: Cruz-Jentoft AJ et al. (Age Ageing 2019). SARC-CalF: Barbosa-Silva TG et al. (J Am Med Dir Assoc 2016). Resistance training in sarcopenia: Peterson MD et al. (Am J Med 2011) — meta-analysis showing significant strength gains with resistance training in older adults.

Clinical Content Trust

Last reviewed:: April 21, 2026
Guideline version:: General evidence framework v2026.04
Source set version:: Primary-source set v1

How to Interpret Your Result

Higher SARC-F scores indicate greater probable sarcopenia risk and functional vulnerability.

When to Use This Tool

Use for rapid sarcopenia risk screening in outpatient geriatrics, primary care, rehabilitation, and preoperative assessments.

Limitations

SARC-F may have limited sensitivity in early sarcopenia and should be complemented by physical performance and strength testing.

Disclaimer: This tool is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider with questions about your health.

Changelog

April 21, 2026 · trust-baseline
Clinical trust metadata enabled for this tool page with structured review/version fields.

Related Tools

Geriatrics

Clinical Frailty Scale

Assess frailty using the Rockwood Clinical Frailty Scale (CFS 1–9): Very Fit to Terminally Ill. Used for hospice eligibility, prognostication, ICU triage, surgical risk stratification, and goals-of-care discussions.

Open Geriatrics

Katz ADL

Assess independence in six basic activities of daily living with the Katz ADL Index. Scores range from 0 (dependent) to 6 (fully independent).

Open Geriatrics

Barthel Index

Assess independence in core activities of daily living with the Barthel Index (0-100), commonly used in rehabilitation and geriatric care.

Open Geriatrics

Timed Up and Go

Assess mobility and fall risk with the Timed Up and Go (TUG) test. TUG >12 seconds indicates high fall risk. Times the performance of standing, walking 3 meters, turning, and returning to seated.

Open

Frequently Asked Questions

SARC-F is a validated 5-item self-report questionnaire for sarcopenia risk screening. The acronym stands for the five items: Strength (difficulty lifting/carrying 10 lbs), Assistance in walking (difficulty walking across a room), Rise from a chair (difficulty getting up from a chair or bed), Climb stairs (difficulty climbing 10 stairs), and Falls (number of falls in the past year). Each item is scored 0–2; total range 0–10. Score ≥4 is the positive screen threshold for probable sarcopenia risk. Developed and validated by Malmström & Morley (2013).

SARC-F score ≥4 is the positive screen threshold for probable sarcopenia risk, endorsed by EWGSOP2 (2019) and AWGS (2019). Scores 0–3 = screen negative (low probability of clinically significant sarcopenia at this time). Score 4 = borderline positive, proceed to objective strength assessment. Scores 5–10 = clearly positive, indicating significant self-reported functional limitation across multiple domains, with high probability of confirming sarcopenia on objective testing. Higher scores correlate with greater severity of functional impairment.

No — SARC-F is a screening tool, not a diagnostic test. A score ≥4 identifies patients at probable risk who need confirmatory objective assessment. Per EWGSOP2 guidelines, confirmed sarcopenia requires: (1) low muscle strength (grip strength <27 kg men, <16 kg women, or sit-to-stand <12 seconds); (2) low muscle quantity (DXA appendicular lean mass index <7.0 kg/m² men, <5.5 kg/m² women, or equivalent BIA threshold). Severe sarcopenia requires additionally low physical performance (gait speed ≤0.8 m/s, SPPB ≤8, or TUG ≥20 seconds). SARC-F triggers the diagnostic pathway — it does not complete it.

SARC-F was developed and initially validated by Malmström TK and Morley JE (J Am Med Dir Assoc 2013) in a primary care population of older adults. Subsequent validation studies have confirmed performance in multiple populations: hospital inpatients (Zhang et al., J Nutr Health Aging 2016), community-dwelling elderly (Woo et al., J Gerontol 2014), Asian populations (Chen et al., AWGS 2014), and cancer patients. Meta-analyses report pooled sensitivity approximately 20–60%, specificity 70–90%, AUC approximately 0.74–0.84. EWGSOP2 (Cruz-Jentoft et al., Age Ageing 2019) and AWGS 2019 both endorse SARC-F as the recommended initial sarcopenia screening step.

Evidence-based sarcopenia treatment: (1) Progressive resistance training — 2–3 sessions per week targeting all major muscle groups at ≥70% 1RM; single most effective intervention. (2) Protein optimization — ≥1.2–1.5 g/kg/day total protein; leucine-enriched whey protein after exercise; distribute protein across 3+ meals. (3) Vitamin D supplementation — if deficient (25-OHD <50 nmol/L); target >75 nmol/L; reduces fall risk and modestly improves muscle function. (4) Omega-3 fatty acids — anti-inflammatory effect; some evidence for augmenting resistance training response in older adults. (5) Treat underlying causes — manage malnutrition, optimize chronic disease control, review medications contributing to muscle weakness (statins, corticosteroids at high doses). (6) Occupational therapy for functional adaptation during rehabilitation.

Online Medical Tools — SARC-F

SARC-F

How It Works

Ask the patient the five SARC-F questions

Sum the five item scores (total 0–10)

Interpret the screen result and plan confirmatory assessment

Who Uses the SARC-F

Primary Care Sarcopenia Screening in Older Adults

Pre-Operative Functional Risk Assessment

Chronic Disease and Oncology Sarcopenia Monitoring

Geriatric Oncology Assessment

Falls Prevention Clinics and Physiotherapy Assessment

Pro Tips

SARC-F is a screener, not a diagnostic tool — always confirm positives objectively

SARC-F has high specificity but moderate sensitivity — negative result doesn't rule out early sarcopenia

The falls item alone (item 5) has independent falls prediction value

Pair SARC-F with objective grip strength for best diagnostic efficiency

Resistance exercise is the single most evidence-based sarcopenia intervention

Protein intake is the key nutritional intervention for sarcopenia

SARC-F is validated and comparable across ethnic groups — key for diverse populations

Vitamin D deficiency is a modifiable sarcopenia risk factor worth checking

Common Questions About Your Results

Evidence-Based Methodology

Clinical Content Trust

How to Interpret Your Result

When to Use This Tool

Limitations

Changelog

Related Tools

Clinical Frailty Scale

Katz ADL

Barthel Index

Timed Up and Go

Further Reading

A Comprehensive Guide to Geriatric Medicine: Assessment Tools and Aging Health

Frequently Asked Questions